Consistent with the concept that most effective cancer therapies are multimodal, combining Treg depletion with active cancer immunotherapeutic interventions is an attractive prospect, supported by abundant data in mice [129] [130] [131] [132] and by preliminary human trials [133] [134] [135] . Lastly, additional strategies aimed to altering regulatory T cell function in cancer immunotherapy, including blocking Treg trafficking, differentiation, and/or function and reducing effector cell susceptibility to suppression, have already proven successful in preliminary studies [136] [137] [138] .